Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan

About 4% of the population in Taiwan are seropositive for anti-HCV Ab and 70% with HCV RNA. To address this high chronic hepatitis C disease load, Taiwan National Health Insurance started reimbursing genotype-specific DAAs in 2017 and pangenotype DAAs in mid-2018. With a 97% SVR12 rate, there were s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chun-Ming Hong, You-Yu Lin, Chun-Jen Liu, Ya-Yun Lai, Shiou-Hwei Yeh, Hung-Chih Yang, Jia-Horng Kao, Shih-Jer Hsu, Yi-Hsiang Huang, Sheng-Shun Yang, Hsing-Tao Kuo, Pin-Nan Cheng, Ming-Lung Yu, Pei-Jer Chen
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	direct-acting antiviral agent chronic hepatitis C treatment failure resistance-associated substitution whole genome sequencing Taiwan Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/4771619952644a0e85cb664e74106a9b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan

Ejemplares similares